Abstracts tagged "immunosuppressants"

Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Tracy M. Frech¹, Maureen Murtaugh², Ami A. Shah³, Jessica K. Gordon⁴, Victoria K. Shanmugam⁵, Robyn T. Domsic⁶, Monique Hinchcliff⁷, Faye N. Hant⁸, Shervin Assassi⁹, Virginia D. Steen¹⁰ and Dinesh Khanna¹¹, ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, The George Washington University, Washington, DC, ⁶Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁸Dept of Medicine, Medical Univ of South Carolina, Charleston, SC, ⁹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹⁰Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ¹¹University of Michigan Health System, Ann Arbor, MI
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…
Abstract Number: 1661 • 2014 ACR/ARHP Annual Meeting
Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares?
Angela Pakozdi¹, Ravindra Rajakariar², Michael Sheaff³ and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom, ³Histopathology, Barts Health NHS Trust, London, United Kingdom
Background/Purpose Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with systemic lupus erythematosus. The role of repeat kidney biopsies (RB)…
Abstract Number: 1260 • 2014 ACR/ARHP Annual Meeting
The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease with Anti- Synthetase Antibodies
Yuji Hosono¹, Ran Nakashima², Yoshitaka Imura³, Naoichiro Yukawa², Hajime Yoshifuji², Takaki Nojima⁴, Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: Interstitial lung disesases (ILD) is the most common cause of mortality in polymyosotis (PM) and dermatomyositis (DM). Cyclosporine had been reported to improve clinical…
Abstract Number: 1051 • 2014 ACR/ARHP Annual Meeting
Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta-Analysis
Jasvinder A. Singh¹, Ahmed Kotb², Alomgir Hossain², Amy Mudano³ and George Wells⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Ottawa, Ottawa, ON, Canada, ³Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁴Cardiovascular Resarch Methods Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose To compare renal remission rates with immunosuppressives by performing a systematic review and network meta-analyses (NMA) of RCTs of lupus nephritis. Methods We performed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].